BridgeBio Pharma, Inc. (BBIO): Price and Financial Metrics

BridgeBio Pharma, Inc. (BBIO)

Today's Latest Price: $35.69 USD

0.37 (1.05%)

Updated May 27 4:00pm

Add BBIO to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

BBIO Daily Price Range
BBIO 52-Week Price Range

BBIO Stock Price Chart More Charts

BBIO Price/Volume Stats

Current price $35.69 52-week high $48.36
Prev. close $35.32 52-week low $14.23
Day low $34.00 Volume 419,100
Day high $36.06 Avg. volume 790,166
50-day MA $28.79 Dividend yield N/A
200-day MA $29.14 Market Cap 4.33B

BridgeBio Pharma, Inc. (BBIO) Company Bio

BridgeBio Pharma, Inc. engages in developing transformative medicines to treat patients who suffer from mendelian diseases. Its pipeline of 15 development programs includes product candidates from early discovery to late-stage development. The firm develops BBP-265, an oral small molecule transthyretin for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers and in preclinical development for the treatment of achondroplasia; and BBP-631, a preclinical adeno-associated virus, gene transfer product candidate, for the treatment of congenital adrenal hyperplasia caused by 21OHD. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.

BBIO Latest News Stream

Event/TimeNews Detail
Loading, please wait...

BBIO Latest Social Stream

Loading social stream, please wait...

View Full BBIO Social Stream

Latest BBIO News From Around the Web

Below are the latest news stories about BridgeBio Pharma Inc that investors may wish to consider to help them evaluate BBIO as an investment opportunity.

BridgeBio Pharma’s Phoenix Tissue Repair Provides Updates to its Recessive Dystrophic Epidermolysis Bullosa (RDEB) Program and Announces New Leadership Appointments

Phoenix Tissue Repair, Inc. (PTR), an affiliate company of BridgeBio Pharma, Inc. (BBIO) today announced updates to its ongoing Phase 1/2 study of PTR-01 (BridgeBio designation BBP-589), an intravenously-administered recombinant collagen 7 protein replacement therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB). RDEB is a rare genetic disorder characterized by severe blistering and scarring of the skin caused by even minor friction or trauma, as well as systemic manifestations including esophageal strictures and dysphagia, corneal abrasions, anemia and nutritional deficiencies. “RDEB is a debilitating disease, and current treatment options are limited to palliative skin care involving daily wound maintenance, protective bandaging, pain and itch management, and t...

Yahoo | May 13, 2020

BridgeBio Pharma, Inc. Reports First Quarter 2020 Financial Results and Business Update

The company is working with its committed partners to minimize disruption from the COVID-19 pandemic on its clinical trials and other drug development programs. Despite the challenges presented by COVID-19, BridgeBio’s clinical trials of infigratinib in tumors with FGFR genetic alterations are proceeding as planned. Certain clinical trials that were in the process of enrolling have slowed as a result of the COVID-19 outbreak.

Yahoo | May 13, 2020

BridgeBio Pharma, Inc. To Present At Upcoming Investor Conference

PALO ALTO, Calif., May 06, 2020 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced today that it will present at the Bank of America Securities 2020 Health Care Conference on.

Yahoo | May 6, 2020

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

PALO ALTO, Calif., May 05, 2020 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on May 1,.

Yahoo | May 5, 2020

Why BridgeBio (BBIO) Stock Might be a Great Pick

BridgeBio (BBIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Yahoo | April 8, 2020

Read More 'BBIO' Stories Here

BBIO Price Returns

1-mo 12.44%
3-mo 17.25%
6-mo 23.07%
1-year N/A
3-year N/A
5-year N/A
YTD 1.83%
2019 N/A
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.145 seconds.